AI Article Synopsis

  • Women with hypothyroidism often need higher levothyroxine doses during pregnancy to maintain healthy thyroid levels.
  • A study analyzed TSH testing frequency and dosage adjustments throughout pregnancy, using data from Alberta, Canada, between 2014 and 2017.
  • Results indicated that while most women had TSH tests, overtreatment (TSH <0.10 mIU/L) was linked to higher preterm delivery risks, but undertreatment (TSH ≥10.00 mIU/L) did not show significant adverse effects.

Article Abstract

Women with hypothyroidism before pregnancy often require an increase in their levothyroxine dosage to maintain a euthyroid state during pregnancy. The objectives of this study were to investigate: (i) the frequency and distribution of thyrotropin (TSH) testing and levothyroxine dosage adjustment by gestational age, (ii) the magnitude of levothyroxine increase by the underlying etiology of hypothyroidism, and (iii) the relationship of overtreatment or undertreatment during pregnancy with adverse pregnancy outcomes among women using thyroid replacement before pregnancy. A retrospective cohort study of pregnancies in women on thyroid replacement before pregnancy in Alberta, Canada, was performed. Women using thyroid replacement anytime during the two years before pregnancy who delivered between October 2014 and September 2017 were included. Delivery records, physician billing, and laboratory and pharmacy administrative data were linked. Outcomes included characteristics of TSH testing, levothyroxine dosing, and pregnancy outcomes. The frequency and gestational timing of TSH testing and levothyroxine adjustments were calculated. Multiple logistic regression was used to test whether pregnancies with TSH <0.10 mIU/L (overtreatment) or TSH ≥10.00 mIU/L (undertreatment) compared with control pregnancies (TSH 0.10-4.00 mIU/L) were associated with adverse pregnancy and neonatal outcomes. Of the 10,680 deliveries, 8774 (82.2%) underwent TSH testing at least once during pregnancy, at a median gestational age of six weeks. An adjustment of levothyroxine dosage was made for 4321 (43.7%) during pregnancy. TSH in pregnancy below 0.10 mIU/L increased the odds of preterm delivery when compared with control pregnancies (adjusted odds ratio, 2.14 [95% confidence interval 1.51-2.78]). TSH ≥10.00 mIU/L during pregnancy was not associated with any adverse pregnancy or neonatal outcomes in the multivariable analysis. Although most women on thyroid replacement before conception had TSH measured at some point during pregnancy, it is concerning that 17.8% did not. Levothyroxine overtreatment in pregnancy was associated with preterm delivery. These findings suggest that clinicians should be careful to avoid overtreatment with levothyroxine in pregnancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110015PMC
http://dx.doi.org/10.1089/thy.2020.0609DOI Listing

Publication Analysis

Top Keywords

women thyroid
16
thyroid replacement
16
replacement pregnancy
12
pregnancy outcomes
12
tsh testing
12
testing levothyroxine
12
pregnancy
10
outcomes women
8
levothyroxine dosage
8
thyroid
5

Similar Publications

Levothyroxine to suppress thyrotropin (TSH) to <0.5 mIU/L following thyroidectomy in differentiated thyroid cancer (DTC) may reduce recurrence in higher-risk DTC. However, there is limited evidence to support guideline recommendations to maintain TSH in the low-normal range of 0.

View Article and Find Full Text PDF

Spitz melanoma is extremely rare, and only a few cases of distant metastases have been reported. Herein, we describe a case of Spitz melanoma with multiple distant metastases. A 37-year-old woman presented with a 5.

View Article and Find Full Text PDF

Introduction: Anti-thyroid antibodies not only cause thyroid dysfunction but have independent adverse outcomes in the fetus and mother during pregnancy and after birth. Chronic lymphocytic thyroiditis as a presentation of immune system deregulation may be associated with a generalized activation of the immune system at the fetus-maternal unit, the placenta. This interference could be associated with pregnancy morbidities in m o t h e r a n d fetus.

View Article and Find Full Text PDF

A case of transient hyperthyroidism induced by placental site trophoblastic tumor.

J Obstet Gynaecol Res

January 2025

Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Bunkyō, Japan.

We report a case of placental site trophoblastic tumor (PSTT) with transient hyperthyroidism. A 29-year-old gravida 2 para 2 woman presented with abnormal genital bleeding 6 months after delivery. Endometrial histology suggested PSTT.

View Article and Find Full Text PDF

Background: Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.

Methods: We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!